This Surveillance, Epidemiology, and End ResultseMedicare analysis included 4033 patients receiving secondline therapy after first-line platinum-based therapy for newly diagnosed stage IIIB/IV nonesmall-cell lung cancer in the pre-immunotherapy era (2007 to mid-2013). Patients received a variety of second-line agents, most commonly pemetrexed, docetaxel, carboplatin/paclitaxel, and gemcitabine. Dyspnea and anemia were the most common AEs. Mean total per-patienteper-month cost was $10,885; and the prognosis was poor. Introduction: Real-world data on current treatment practices for nonesmall-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. Patients and Methods: This retrospective cohort study identified patients ! 65 years old in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database with first-time diagnosis of stage IIIB/IV NSCLC from 2007-2011 who received second-line therapy after first-line platinum-based chemotherapy from 2007 through mid-2013. Second-line regimens, health care resource use, adverse events (AEs), and associated costs were analyzed descriptively. Overall survival was determined by Kaplan-Meier test. Costs were adjusted to 2013 US dollars. Results: We identified 4033 patients with advanced NSCLC who received second-line therapy (47% of those who received first-line platinum-based chemotherapy). Mean (SD) age was 73 (5) years, 2246 (56%) were male; 1134 (28%) and 2899 (72%) had squamous and nonsquamous NSCLC, respectively. The 4 most common second-line regimens were pemetrexed (22%), docetaxel (12%), carboplatin/paclitaxel (11%), and gemcitabine (7%). Median overall survival from second-line therapy initiation was 7.3 months (95% confidence interval, 7.0-7.7). Dyspnea and anemia were the most common AEs of interest, affecting 29% and 26% of patients, respectively; atypical pneumonia was associated with the highest AE-related costs (mean, $5339). The mean total per-patienteper-month cost was $10,885; AE-related per-patienteper-month costs totaled $1036 (10%). Costs were highest for pemetrexed-treated patients. Conclusion: These real-world data illustrate the variety of second-line regimens, poor prognosis, and high cost of second-line chemotherapy for patients with advanced NSCLC treated before the approval of immunotherapies for these patients.
Introduction
Lung cancer is the leading cause of cancer-related deaths in both women and men in the United States, projected to cause an estimated 154,000 deaths in 2018, or more than one quarter of all cancer-related deaths. 1 Nonesmall-cell lung cancer (NSCLC), which comprises 85% of lung cancer cases, is usually detected after regional or distant metastases have occurred (stage IIIB or IV), when 5-year survival rates are 5% or lower. 1, 2 Before 2015, the recommendations for systemic therapy of advanced (nonresectable) NSCLC comprised first-line therapy with platinum-based chemotherapy, with or without molecular targeted therapy, and, as necessary, second-line therapy with docetaxel, pemetrexed, gemcitabine, or erlotinib. 3, 4 All of these agents, except erlotinib for patients with epidermal growth factor receptor (EGFR) wild-type tumors, are still commonly used options in the current guidelines, although often administered as third-line or later therapy after immunotherapy for eligible patients. The options for treating lung cancer have expanded rapidly in recent years with the development of targeted therapies and immunotherapies, as well as improved molecular testing for predictive biomarkers. [5] [6] [7] Indeed, there were 8 updates to the National
Comprehensive Cancer Network (NCCN) guidelines for managing NSCLC from January 2015 to January 2016. 8 Knowledge of realworld treatment practices and health care resource utilization (HCRU) is needed to understand the place in therapy and the economic impact of newer therapies, as well as current unmet medical needs. 9, 10 There is little published observational data, and none recent, on adverse event (AE) occurrence and costs associated with second-line treatment regimens for NSCLC. [11] [12] [13] The direct medical costs of lung cancer were an estimated $12.1 billion in 2010 and are expected to rise to $15.2 billion by 2020. 14 The aims of this retrospective observational study were to determine and describe recent real-world treatment practices, overall and NSCLC-specific survival, AE occurrence, and associated costs for patients 65 years and older with newly diagnosed advanced NSCLC (stages IIIB/IV) who received first-line platinum-based chemotherapy. Here we describe our findings in the second-line setting for patients with advanced NSCLC who had received platinum-based chemotherapy. A companion paper describes the findings in the first-line setting. 15 
Patients and Methods

Data Source
This retrospective cohort study drew on the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, a collaborative effort of the National Cancer Institute, SEER Registries, and the Centers for Medicare and Medicaid Services. 16 The SEER-Medicare database combines clinical, demographic, and cause of death information for persons with cancer from the SEER cancer registry with longitudinal administrative Medicare claims; 93% of persons age 65 and older in the SEER files are matched to the Medicare enrollment file. 17 The Medicare claims data provide detailed information about covered health care services from the time of Medicare eligibility (at age 65, or younger if disabled or having end-stage renal disease) until death, including dates of service and coded diagnoses and procedures. 18 At the time of this study, the SEER cancer registry contained data on incident cancer cases between 1991 and 2011 covering approximately 28% of the US population, and the Medicare claims data were available through December 2013. 18 
Study Design and Patients
We included patients age 65 years and older at the time of a firsttime diagnosis of advanced/metastatic NSCLC (stage IIIB or IV) from January 1, 2007, to December 31, 2011 , and who received first-line platinum-based chemotherapy for advanced/metastatic NSCLC between January 1, 2007, and June 30, 2013 . The diagnosis of NSCLC was based on the SEER collaborative stage, described in detail elsewhere, 19 with SEER cancer diagnosis code; 20 the date of NSCLC diagnosis was defined as the index date. Eligible patients had to have continuous enrollment in Medicare Part A (inpatient care) and Part B (outpatient services) with no health maintenance organization (HMO) enrollment during the entire observational period, which began 6 months before the index date (baseline period) and ended with death, the date of HMO enrollment, the last date of follow-up in the SEER-Medicare database, or study completion on December 31, 2013, whichever occurred first. Exclusion criteria included multiple primary cancers as reported in the SEER cancer registry or a switch within the first 29 days of starting first-line platinum-based chemotherapy to an EGFR tyrosine kinase inhibitor or anaplastic lymphoma kinase inhibitor, information that was captured via National Drug Codes in the Durable Medical Equipment file (Supplemental Methods in the online version). The study sponsor (Merck & Co., Inc., Kenilworth, NJ) obtained institutional review board approval for using the SEERMedicare database. Informed consent was not required because this was a database analysis using deidentified claims.
Outcome Measures
Antineoplastic treatment regimens were captured in claims with the Health care Common Procedures Coding System or National Drug Code numbers for specific agents. 21, 22 We did not include data from Medicare Part D; therefore, most oral antineoplastic agents were not included unless they were recorded in the claims that we used (Supplemental Methods in the online version). For the purpose of this study, first-line therapy was defined as platinumbased chemotherapy (monotherapy or therapy in combination with other nontargeted anticancer therapies) commencing within 30 days before to 90 days after the date of the recorded NSCLC diagnosis.
We defined the end of first-line therapy as occurring when a 42-day period with no treatment was observed or when a second drug or regimen started on or after day 30. Reinitiation of the same drug or regimen after a 42-day gap, or start of a second drug or regimen on or after day 30, was considered the start of second-line therapy, as per the algorithm of Davidoff et al. 23 Using this algorithm, continuation maintenance therapy (ie, a first-line drug continued as maintenance therapy after a gap of 21-41 days) would be captured as first-line therapy, whereas any switch therapy drug initiated after 30 days would be captured as second-line therapy. The line of therapy was not advanced from first to second line if cisplatin was substituted for carboplatin (or vice versa), paclitaxel was substituted for nab-paclitaxel, or bevacizumab was added to a chemotherapy e784 -Clinical Lung Cancer September 2018
Second-Line Therapy for Advanced NSCLC background; additional rules for advancing the line of therapy are described in the Supplemental Methods in the online version. The end of second-line therapy and end of follow-up occurred when a 42-day period was observed after the last dose of the secondline regimen or if a new drug or regimen started on or after day 30 after the first dose of the second-line regimen, signifying a switch to third-line therapy. The duration of treatment was derived as the time (calculated in days) elapsed from the first cycle received to the date of the next line regimen or 42 days after the last cycle, whichever occurred first. We determined overall survival (OS) and NSCLC-specific survival at 1 year after the initiation of second-line therapy and at the end of the study.
We identified the events of interest for this study (hereafter called AEs of interest) as the grade 3/4 AEs with incidence of ! 5% contained in the US prescribing information of drugs used in therapy for advanced NSCLC. We restricted the AE list to those events requiring HCRU (not lab investigations), based on the Common Terminology Criteria for Adverse Events (CTCAE) description and clinical input. The full list of AEs of interest can be found in the Supplemental Methods in the online version. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 24 used to identify these AEs have been previously reported. 15 The occurrence of any of the AEs of interest was assessed for each patient from the start until the end of second-line therapy, as detailed above. We determined the frequency of each AE and the HCRU events during second-line therapy, including inpatient, emergency, outpatient, skilled nursing facility, and hospice visits. For each HCRU event, we determined the overall number and the number per patient per month (PPPM), calculated as the total divided by the total person days during second-line therapy and multiplied by 30. In addition, we tabulated the mean length of inpatient hospitalizations and stays at skilled nursing facilities.
All claims with an AE of interest coded as the primary diagnosis were attributed to that AE, together with any related claims. Thus, for example, the total cost of an inpatient hospitalization, including all claims for that hospitalization, was defined as AE-related if the AE was the primary diagnosis for at least one claim. We determined the mean per-patient cost and the PPPM costs for total HCRU-related costs, for drug and drug administration costs (Supplemental Table 1 in the online version), and for 2 overlapping categories of costs: (1) AE-related costs (ie, those with the AE as the primary diagnostic code plus related claims) and (2) all other NSCLC-related costs, which included the costs identified in claims with a primary diagnosis of lung cancer (ICD-9-CM code, 162.x) 24 as well as all other HCRU-related costs during second-line therapy. In addition, we calculated the PPPM costs after patients initiated second-line therapy by 5 time intervals after the initiation of first-line therapy and for terminal care in the last 30 days of life for patients who died during the study (Supplemental Methods in the online version). Costs were derived from Medicare claims and included the amount paid by Medicare and by patients and other payers.
Statistical Analysis
We described patient demographic and disease-related characteristics, treatment patterns, occurrence of AEs, and AE-related and all other NSCLC-related HCRU and costs in the second-line setting. Mean and standard deviation (SD) were reported for continuous and count variables, while number and percentage were reported for categorical variables. The SDs for HCRU and cost variables were calculated using Poisson distribution assumption. OS and NSCLC-specific survival were analyzed using the Kaplan-Meier method to determine median OS and the associated 95% confidence interval (CI). Costs were evaluated in US dollars (USD), adjusted to 2013 USD using the Consumer Price IndexeAll Urban Consumers. 25 No formal sample size and power calculations were performed since this was a descriptive, exploratory study, and no hypothesis was tested. Statistical analyses were conducted by SAS 9.3 and 9.4 (SAS Institute, Cary, NC).
Results
Patients
We identified 29,720 patients with initial diagnosis of stage IIIB/ IV NSCLC from 2007 to 2011 who had available treatment data; of these patients, 13,742 (46%) received systemic therapy for NSCLC ( Figure 1 ). A total of 8542 (62%) of 13,742 patients met all study eligibility criteria and received first-line platinum-based chemotherapy, and 4033 (47%) of 8542 continued to second-line therapy and were included in the analyses. The dates of second-line therapy initiation ranged from March 16, 2007 , to December 16, 2013 .
The majority of patients were male (56%) and white (88%); the mean (SD) age was 73 (5) years (Table 1) . We found regional variations in patient representation, with the most patients located in the west (38%) and the fewest in the Midwest (13%). Two-thirds of patients had stage IV NSCLC at diagnosis, and 38% of those with known tumor size had a tumor larger than 5 cm.
Approximately one third of patients had squamous NSCLC (28%) and two thirds had nonsquamous NSCLC, including 1936 (48% overall) with adenocarcinoma (Table 1) . Patients with squamous histology were more likely to be male (64% vs. 52% in the nonsquamous cohort), to have received a initial diagnosis at stage IIIB rather than stage IV (40% vs. 29%, respectively), and to have an adjusted Charlson comorbidity index score of > 0 (38% vs. 32%, respectively). Of those with known tumor size, patients in the squamous cohort were also more likely to have tumors > 5 cms (49% vs. 33% in the nonsquamous cohort) and to have no distant metastasis (22% vs. 9%, respectively; Table 1 ).
Second-Line Therapy for NSCLC
Single agents were administered to approximately one half of patients (46% in squamous and 50% in nonsquamous cohorts), followed by carboplatin doublets (38% and 25%, respectively). The most common second-line regimens are summarized in Table 2 for all patients and by NSCLC histology. The 4 most common regimens overall were pemetrexed (22%), docetaxel (12%), carboplatin and paclitaxel (11%), and gemcitabine (7%). Docetaxel and carboplatin/paclitaxel were more commonly administered to patients with squamous as compared with nonsquamous NSCLC (17% vs. 11% and 18% vs. 9%). Instead, pemetrexed was administered more commonly in the nonsquamous cohort (26% vs. 12% in the squamous cohort; Table 2 ), although it is notable that pemetrexed was used at all for squamous NSCLC as it is not approved for patients with squamous histology.
A relatively large number of patients received carboplatin/paclitaxel (11%) as second-line therapy, using our definition of second line as therapy received after a ! 42-day gap in systemic therapy. The majority of these patients (293/461, 64%) had received carboplatin/paclitaxel in first-line, and it is unclear if this gap was because of toxicity or the regimen was reinitiated upon tumor progression.
The median duration of second-line therapy was 2.7 months (range 2 days to 58.3 months) overall. In the squamous cohort, the median duration was 2.4 months (range 2 days to 38.8 months) and in the nonsquamous cohort, 2.8 months (range 3 days to 58.3 months). Of the most common second-line regimens, the duration of therapy was longest for pemetrexed (median 2.8 months; range 4 days to 55.2 months). In general, regimens were administered for shorter median times in the squamous than the nonsquamous cohort (Supplemental Table 2 in the online version). For example, in the squamous cohort, the median duration of pemetrexed therapy was 2.1 months (range 6 days to 27.4 months); in the nonsquamous cohort, the median duration was 2.8 months (range 4 days to 55.2 months).
Overall Survival
From the initiation of second-line therapy, the median OS was 7.3 months (95% CI, 7.0-7.7), and the median NSCLC-specific survival was 8.0 months (95% CI, 7.8-8.4). Median OS (95% CI) by histology was 6.4 (6.0-7.0) and 7.8 (7.3-8.0) months for the squamous and nonsquamous cohorts, respectively. At 1 year after initiating second-line therapy, the all-cause mortality was 67%, mortality from lung cancer was 63%, and that from other causes was 11% (percentages calculated using the KaplanMeier method to account for censoring). At the end of the study, 390 (10%) patients were alive, including 107 (9%) and 283 (10%) in squamous and nonsquamous cohorts, respectively; of the 3643 deaths, 3077 (84%) were attributed to lung cancer (Supplemental Table 3 in the online version).
Occurrence of AEs and Associated Health Care Resource Use and Costs
The 5 most common AEs of interest recorded during second-line therapy were dyspnea, anemia, hypertension, atypical pneumonia, and fatigue (Table 3 ). The mean cost of AE-related treatment was highest for atypical pneumonia ($5339), which was associated with the greatest frequencies of hospitalizations and skilled nursing facility visits during the study and the longest hospital stays (Table 3 , 
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Supplemental Table 4 in the online version). Anemia was the next most costly AE (mean cost $2392), followed by fatigue ($784), dyspnea ($595), and hypertension ($256). Dyspnea was the most common AE to result in an emergency visit (Supplemental Table 4 in the online version). Overall, all 5 types of AEs were most commonly treated in outpatient visits (Table 3) , and none was associated (as a primary diagnosis) with hospice care. While inpatient stays and skilled nursing facility visits were less common than outpatient visits, the mean costs were much higher, especially for anemia and atypical pneumonia. The frequency of dyspnea and anemia in association with the 4 most common second-line regimens generally followed the overall pattern, with dyspnea being the most common AE and anemia the second most common (Table 3) . Among patients who received docetaxel or gemcitabine, atypical pneumonia was the third most common AE, recorded for 18% of patients in each treatment cohort and resulting in several hospitalizations and, for 10% to 12% of patients, an emergency visit (Table 3, Supplemental Table 4 in the online version).
The AE-related PPPM costs represented approximately 10% ($1036/10,885) of the total PPPM costs, and the drug and drug administration costs represented approximately 39% ($4246/10,885; Table 4 ). With regard to the most common treatment regimens, costs attributed to AEs ranged from 9% (pemetrexed) to 13% (gemcitabine) of total costs, and costs attributed to drugs and drug administration ranged from 4% (carboplatin/paclitaxel) to 49% (pemetrexed) of total costs. The total PPPM cost for patients treated with pemetrexed was higher than PPPM costs for treating all patients and for patients treated with carboplatin/paclitaxel, docetaxel, or gemcitabine (Table 4 ). The PPPM costs by time interval are presented in Supplemental Table 5 in the online version.
Of the mean total PPPM cost of $10,885 during second-line therapy, $9804 (90%) was associated with outpatient claims ($1658 for emergency and $8146 for outpatient visits). The remainder of the mean total cost was broken down into $732 (7%), $181 (2%), and $168 (2%) for claims associated with inpatient, skilled nursing facility, and hospice visits, respectively.
Discussion
We found that approximately half of patients included in the US SEER-Medicare database who presented with advanced NSCLC continued to second-line therapy after receiving first-line platinumbased chemotherapy. Many different second-line regimens were administered during our study period (2007-2013); the most Second-Line Therapy for Advanced NSCLC e788 -Clinical Lung Cancer September 2018 common ones were pemetrexed, docetaxel, carboplatin/paclitaxel combination, and gemcitabine. Patients with squamous NSCLC most commonly received carboplatin/paclitaxel (18%) or docetaxel (17%), while those with nonsquamous NSCLC most commonly received pemetrexed (26%). Of the AEs of interest, dyspnea and anemia were the most common across all cohorts, while atypical pneumonia was associated with the highest AE-related costs. The AE-related costs represented approximately 10% of the total costs. As expected for NSCLC treatment, overall, the majority of claims were associated with outpatient care (outpatient and emergency
Figure 2 Kaplan-Meier Plots Depicting Overall Survival From Initiation of Second-Line Therapy (A) for All Patients and (B) for Patients Who Received 6 Most Common Second-Line Regimens
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Clinical Lung Cancer September 2018 -e789 Second-Line Therapy for Advanced NSCLC e790 -Clinical Lung Cancer September 2018 visits). Pemetrexed-treated patients incurred greater mean costs than patients treated with other common second-line regimens. The second-line treatment patterns we identified are generally in line with those reported in prior US observational studies of advanced NSCLC, in particular the wide variation in regimens 11, [26] [27] [28] [29] [30] [31] [32] and the notable lack of adherence to second-line guideline-based treatment in advanced NSCLC. 11, 26 Many prior studies did not distinguish regimens by NSCLC histologic type. 11,29-32 While we examined treatment patterns separately for squamous versus nonsquamous histology, we did not include data from Medicare Part D. Therefore, patients who received oral drugs for second-line therapy (eg, targeted therapies such as erlotinib, which is now not approved in this setting) were not included in our study, resulting in some discrepancy with prior work. For example, a study of the same time period (2008-2013) that included mostly patients with nonsquamous histology (87%) found that the most common second-line agents overall were pemetrexed (22%), erlotinib (17%), docetaxel (11%), carboplatin with paclitaxel (7%), and gemcitabine (7%). 29 For patients with squamous NSCLC diagnosed from 2001 to 2009 in the SEER-Medicare database, the 4 most common regimens were similar to those we identified, namely, gemcitabine, docetaxel, carboplatin/paclitaxel, and pemetrexed. 26 Moreover, in the latter study, second-line therapies were not always consistent with treatment guidelines, in particular with regard to administration of pemetrexed to patients with squamous histology, comprising 11% of patients in that study and 12% in our study, despite changes to the pemetrexed label in September 2008 removing the indication for squamous NSCLC. 33 This raises an important issue that a large proportion of patients are receiving regimens that do not follow guidelines, and for which there are data showing lack of efficacy. It is also likely that these patients may have higher resource use and poor outcomes given that they may not fully benefit from treatment but may still have AEs.
We found that the median duration of second-line therapy was quite short (2.7 months overall), as reported by others, 28 and survival was poor, with 1-year all-cause mortality of 67% and NSCLCrelated mortality of 63%. Only 10% of patients were alive at the end of the study. The median OS of 7.8 months for nonsquamous NSCLC was similar to that in a prior second-line study (7.5 months). 27 As expected, the median OS was inferior for patients with squamous as compared with nonsquamous NSCLC (6.4 vs. 7.8 months from initiation of second-line therapy, respectively). 34 A recent review by Abbreviations: AE ¼ adverse event; NSCLC ¼ nonesmall-cell lung cancer. a Costs are those associated with any claim. All claims with AE of interest coded as primary diagnosis were attributed to that AE, together with any related claims; thus, there is some overlap between AE-related costs and other NSCLC-related costs. b Overall total cost includes other payer costs in addition to Medicare and patient costs.
Clinical Lung Cancer September 2018 -e791 NSCLC as 9 to 11 months versus 12 to 14 months for nonsquamous NSCLC in most clinical trials, whereas Bradley et al 35 report a median OS of 9.2 months in 2011 for SEER-Medicare patients with advanced NSCLC who received systemic therapy. The lower OS in the present study is calculated from initiation of second-line rather than first-line therapy, applies to an older patient population that likely has poorer outcomes than those in enrolled in clinical trials, and excludes patients receiving targeted therapies such as erlotinib. In fact, the earlier study of Karve et al 30 While the SEER-Medicare database includes only patients ! 65 years of age, it captures a large proportion of patients with NSCLC in the SEER catchment areas. The average age at diagnosis of advanced NSCLC is about 70 years, and approximately two thirds of patients are 65 years or older at diagnosis. 36 The demographic and clinical characteristics of our patient population were thus quite consistent with the wider population of patients with advanced NSCLC, including the one-third versus two-thirds split of squamous versus nonsquamous histology, respectively, and the fact that adenocarcinoma was the most common histologic type. 37 Patients in our study with squamous NSCLC were majority male, while the patients with nonsquamous NSCLC were approximately evenly divided between men and women. Overall, 46% of eligible patients received chemotherapy, a higher percentage than in earlier studies of advanced NSCLC using the SEER-Medicare linked database (31% to 38%), [38] [39] [40] and of patients on Medicare (37%), 41 and similar to the 46% of patients ! 65 years old who received chemotherapy in a study using 2002-2007 data from HMOs participating in the Cancer Research Network. 42 Recent US survey data indicate that the proportion of patients receiving chemotherapy for advanced NSCLC has increased over time from 1996 to 2010, 41 yet our study demonstrates that a considerable proportion of patients do not receive systemic therapy, particularly consecutive lines of therapy.
There are few prior observational data on AE occurrence and costs by second-line treatment regimen, and differences in study design and patient population preclude direct comparisons of our results to those of prior studies. Nonetheless, one study examining all second-line therapies, 11 and 2 studies focused only on docetaxel, erlotinib, or pemetrexed as second-line monotherapy, 12, 13 concluded, similar to our study, that costs were highest for patients prescribed pemetrexed. The mean total PPPM costs during second-line therapy in this study were $10,885 in 2013 USD, with the AE-related costs comprising 10% of the total. By contrast, Lash et al 12 found AErelated costs to be 49% to 62% of total health care costs for patients receiving pemetrexed or docetaxel, a much higher proportion of total costs than in our study; however, this could be because they included all costs recorded with any AE code. Instead we included only the costs associated with AEs as the primary diagnosis code on the claim, plus related claims. The costs varied greatly according setting of care, with mean costs notably higher for inpatient stays and skilled nursing facility visits. While these were less common than outpatient visits, the differences in mean costs provide strong rationale for early detection of AEs and identifying methods to enable patients to avoid having to enter these high-cost settings. Prior studies report use of platinum doublets in second line, 11, 26, [28] [29] [30] and we found that a large number of patients in our study received platinum doublet during second line, of which many received the same regimen during first-line therapy as well. This subset of patients could be receiving first-line therapy after a gap of ! 42 days for toxicity or other intervening events, or they may be getting retreated after a relapse. These patients had appeared to have better survival and lower AE-related PPPM costs compared with patients receiving pemetrexed, suggesting they may have had tumors that responded particularly well to a platinum doublet in first line and thus had a long progression-free interval. We note that this approach, namely, retreatment with a platinum doublet in secondline if there is a long progression-free interval, is standard of care in small cell lung cancer. 43 Several limitations of this study require consideration. While patients were well-characterized with regard to demographic characteristics and NSCLC histology, the SEER-Medicare database does not include smoking status or information on performance status. Moreover, the database does not include the clinical information necessary to determine if or when progression or treatment failure occurred, hence we used an algorithm based on that of Davidoff et al 23 to distinguish between first-and second-line regimens. We acknowledge that the patient population was quite heterogeneous, and we cannot rule out the possibility that some agents counted as second-line therapy were actually a continuation of first line after a treatment holiday as discussed above, or a combination of secondand third-line therapy. Moreover, contamination with maintenance therapy is a possibility, such as the inclusion of switch maintenance therapy started 42 days or more after completion of the platinum doublet. The AEs were identified based on ICD-9 codes and thus a causal relationship with antineoplastic therapy cannot be established with certainty. Moreover, we were able to include only patients with NSCLC diagnosis through 2011 and Medicare claims data through 2013, and we could identify only patients with initial diagnosis of stage IIIB/IV NSCLC, thereby excluding those with NSCLC recurrence or progression from earlier to advanced stages. The database includes only patients older than 65; thus, results cannot be generalized to younger ages. In addition, because predictive molecular biomarker results are not available in the database, we were unable to analyze treatment patterns by biomarker status. As with all retrospective studies, there may be unmeasured confounding factors or unidentified sources of bias. For example, while we were able to measure and report drug, AE-related, and NSCLCrelated costs, there may be other unmeasured costs associated with disease progression accruing from the use of a less expensive but also less effective agent. Finally, this study identified direct costs that were derived from Medicare claims and included the amount paid by Medicare and by patients and other payers. We were not able to assess, hence did not include, the costs of supplemental medications or indirect costs, such as those associated with travel or time off work for patients or care-givers.
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We studied treatment patterns in the second-line setting for patients who received first-line platinum-based chemotherapy to understand HCRU and costs for one of the patient populations eligible to receive the newer immunotherapy drugs. We included the most recent data available from SEER-Medicare on resource use and costs at the time of the study, and we described treatment patterns according to NSCLC histology. The SEER-Medicare data are wellvalidated and have been widely adopted for studies of this type. 16 Further research is needed for this patient population to include the now-approved first and second line immunotherapies. Also it would be worth exploring resource use and outcomes for a subgroup of patients who were retreated with platinum doublet after first-line therapy, for which there are data suggesting a lack of survival benefit, 44 but a suggestion of benefit in our population. In addition it would be of interest to evaluate the outcomes of patients with squamous NSCLC who received off-label pemetrexed. Further observational research using the SEER-Medicare data, and using other databases to capture the full age range of patients with advanced NSCLC, is needed to update and expand on our findings. Moreover, cost-effectiveness analyses comparing second-line therapies by applying established quality-adjusted life-year figures would be of interest.
Conclusion
In this retrospective observational study, after first-line platinumbased chemotherapy, patients 65 years and older with advanced NSCLC received a variety of second-line agents in the preimmunotherapy era, most commonly pemetrexed, docetaxel, carboplatin/paclitaxel, and gemcitabine. The prognosis for these patients is poor, with mortality of 67% at 1 year, and overall PPPM costs of second-line therapy of over $10,000 and highest for patients prescribed pemetrexed. Further research is needed to update our findings, to document the use and costs of oral second-line therapies for this patient population, and to understand the reasons underlying the low fraction of patients receiving any second-line therapy, the heterogeneous treatments administered to this population, and the reasons for nonadherence to treatment guidelines.
Clinical Practice Points
There is little published observational data, and none recent, on real-world treatment patterns by histology of NSCLC and HCRU, AE occurrence, and costs associated with second-line treatment regimens for NSCLC. Understanding current treatment patterns and clinical outcomes of NSCLC is important for understanding the state of therapy and the potential impact of newer therapies, in addition to defining unmet medical needs. We found that only 47% of patients ! 65 years old administered first-line platinum-based chemotherapy for stage IIIB/IV NSCLC received a second-line regimen (n ¼ 4033). Many different second-line regimens were administered during our study period (2007) (2008) (2009) (2010) (2011) (2012) (2013) ; the most common ones were pemetrexed, docetaxel, carboplatin/paclitaxel combination, and gemcitabine. Approximately 12% of patients with squamous NSCLC received pemetrexed despite the removal of this indication in 2008. The lack of adherence to second-line guideline-based treatment in advanced NSCLC was notable.
Dyspnea and anemia were the most common AEs, and atypical pneumonia was associated with the greatest AE-related costs. The mean total PPPM cost was $10,855, with AE-related costs comprising 10% of total costs. Median survival was only 7.3 months from the initiation of second-line therapy. While inpatient stays and skilled nursing facility visits were less common than outpatient visits, the mean costs were much higher, illustrating the need for early detection of AEs and providing care to help patients avoid entering these high-cost settings. Further research is needed to understand the reasons underlying the low fraction of patients receiving any second-line therapy, the heterogeneous treatments administered to this population, and the reasons for nonadherence to treatment guidelines.
